B+
Bull case
30%
Probability
Target price
$420.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
KRYS
Krystal BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
VYJUVEK's 24% year-over-year second-quarter revenue growth, 95% gross margin and Krystal's reported $1.1 billion in cash and investments support funding for expansion and clinical programs. A favorable KB803 readout could add a second product opportunity.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.9.
What can break
A negative or ambiguous KB803 registrational readout could delay a second-product thesis. [#SEC-8K-2026-08-03]
Momentum
63
Value
59
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $342.00 · Bull $420.00 · Bear $245.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $395.44
Why
Momentum63 · Δ7d +1.2
Value59 · Δ7d -0.1
Sentiment66 · Δ7d +2.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +2.9.
Contradictions & invalidation
- • A negative or ambiguous KB803 registrational readout could delay a second-product thesis. [#SEC-8K-2026-08-03]
- • Combined 2026 non-GAAP R&D and SG&A guidance of $175 million–$195 million excludes stock-based compensation, limiting comparison with GAAP expense. [#SEC-8K-2026-08-03]
- • VYJUVEK remains the sole marketed product.
Catalyst clock
2026-12-31
KB803 IOLITE readout
Lead driver: Sentiment · See AI snapshot
Momentum
63
8% active weight
Current posture
7d trendFlat
Δ7d
+1.2
Δ21d
+12.7
Value
59
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.6
Sentiment
66
45% active weight
Current posture
7d trendFlat
Δ7d
+2.9
Δ21d
-6.1
Why this grade
Composite grade A. Momentum 62.8 / Value 59.3 / Sentiment 65.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$342.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$245.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$9.22B
Beta
0.49
Shares Out
29.6M
P/E (TTM)
36.7
P/S (TTM)
19.02
P/FCF (TTM)
42.85
Rev YoY
+24.1%
EPS YoY
+38.6%
Gross Margin
+93.3%
Op Margin
+44.9%
Net Debt
-$818.45M
Current Ratio
8.32
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data